Headache and Migraine

Food insecurity and migraine, anxiety sensitivity and migraine severity, supraorbital stimulation to prevent chronic migraine-find summaries of these and other recent findings here.

The neurological symptoms of migraine aura are generally attributed to cortical spreading depression/depolarization, although that hypothesis does have its detractors. The question of whether CSD triggers migraine headache remains controversial.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.

The professor of neurology at both the University of California San Francisco and King’s College, London, spoke about the results from a phase 2b/3 study evaluating atogepant for prevention of migraine.

Neurology News Network for the week ending June 8, 2019.

Emgality (galcanezumab-gnlm) is the first FDA-approved drug that reduces the frequency of headache attacks.

The program director of neurology at Zucker School of Medicine, Northwell Health, reviewed the contributions of neurologist S. Weir Mitchell, MD, and how today’s neurologists can gain insights for their own practice from Mitchell’s complicated history.

Galcanezumab, an anti-CGRP antibody, is now the first approved therapy for the treatment of episodic cluster headache just 9 months after receiving approval for the preventive treatment of migraine.

Neurology News Network for the week ending June 1, 2019.

Results of a pooled analysis of 3 clinical trials suggest that the magnitude of fingolimod’s treatment effect in MS is not affected by the presence of migraine or headache in patients.